A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer

Highlights • Feasibility of adjuvant cisplatin or carboplatin + pemetrexed in Stage IB/II NSCLC. • Feasibility definition based on safety, tolerability, and dose-intensity parameters. • Neither treatment met the pre-defined feasibility level >60% of patients. • Feasibility >81% (both treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-12, Vol.90 (3), p.397-404
Hauptverfasser:	Schmid-Bindert, Gerald, Engel-Riedel, Walburga, Reck, Martin, Schuette, Wolfgang, Stöhlmacher, Jan, Fischer, Jürgen R, Mazières, Julien, Chouaid, Christos, Wolf, Martin, Vinolas, Nuria, Soldatenkova, Victoria, Ripoche, Veronique, Nguyen, Tuan, Visseren-Grul, Carla
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant Cisplatin - administration & dosage Feasibility Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - surgery Male Middle Aged Neoplasm Staging NSCLC Pemetrexed Pemetrexed - administration & dosage Pulmonary/Respiratory Risk Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Feasibility of adjuvant cisplatin or carboplatin + pemetrexed in Stage IB/II NSCLC. • Feasibility definition based on safety, tolerability, and dose-intensity parameters. • Neither treatment met the pre-defined feasibility level >60% of patients. • Feasibility >81% (both treatments) in a post-hoc analysis considering only safety. • Both treatments showed good safety-related feasibility and tolerability.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.11.007